Transferosomes in Topical Antifungal Therapy: Advancements, Challenges, and Future Perspectives

Introduction

Superficial fungal infections of the skin, nails, and mucosal surfaces are among the most widespread dermatological conditions worldwide. These infections are primarily caused by dermatophytes (such as Trichophyton, Microsporum, and Epidermophyton species), yeasts (notably Candida spp. and Malassezia spp.), and certain non-dermatophyte molds. While these infections are rarely life-threatening, they can cause significant discomfort, aesthetic concerns, secondary bacterial infections, and psychological distress in affected individuals. In immunocompromised patients, even superficial fungal infections can progress into more severe, invasive forms [1-2]. Thus, effective and sustained antifungal treatment remains essential for both clinical resolution and prevention of recurrence.

Conventional topical antifungal agents, including clotrimazole, miconazole, econazole, ketoconazole, and terbinafine, are widely used as first-line therapies [3]. These drugs act by disrupting the fungal cell membrane or inhibiting ergosterol synthesis, an essential component of fungal membranes. However, clinical outcomes are often suboptimal due to several critical limitations. One of the primary challenges is poor drug solubility, which limits the amount of drug that can be incorporated into topical formulations. Additionally, insufficient skin penetration, especially into deeper layers of the epidermis and dermis where fungal elements may reside, leads to reduced therapeutic efficacy [4]. Other complicating factors include drug degradation, frequent application requirements, patient non-compliance, and the emergence of antifungal resistance.

To overcome these limitations, researchers have turned to nanocarrier-based drug delivery systems as promising tools to improve the delivery and performance of antifungal agents. These systems include liposomes, niosomes, solid lipid nanoparticles, and more recently, transferosomes. Among these, transferosomes have garnered particular attention due to their unique ultra-deformable nature, which enables them to penetrate the stratum corneum more effectively than conventional vesicles [5]. Developed in the early 1990s, transferosomes are composed of phospholipids and an edge activator—typically a surfactant such as sodium cholate, Tween 80, or Span 80—which destabilizes the lipid bilayer and imparts high elasticity to the vesicle.

This Fig 1 illustrates the structural composition and transdermal drug delivery mechanism of transferosomes. The diagram shows phospholipid bilayers embedded with edge activators (e.g., surfactants) forming ultra-deformable vesicles. These vesicles penetrate the stratum corneum through intercellular pathways driven by hydration gradients. Once inside the deeper skin layers, the transferosomes release the encapsulated antifungal agent in a controlled manner, ensuring localized therapeutic action with enhanced efficacy and minimal systemic exposure.

The stratum corneum—the outermost layer of the skin—is the main barrier to drug permeation. It consists of tightly packed keratinized cells embedded in a lipid matrix, making it highly resistant to hydrophilic and even many lipophilic drugs [6]. Traditional topical formulations often fail to deliver adequate drug concentrations beyond this barrier. Transferosomes, however, can deform and pass through skin pores much smaller than their own diameter, propelled by the transdermal water gradient. This property allows them to deliver encapsulated antifungal drugs into deeper skin layers without the need for chemical enhancers or mechanical disruption of the skin, transferosomes protect drugs from enzymatic degradation and improve drug bioavailability, potentially allowing for lower dosagesand less frequent applications, thereby improving patient compliance. Their biocompatibility, versatility in encapsulating both hydrophilic and lipophilic drugs, and potential for targeted delivery add to their appeal as advanced drug carriers [7]. Several in vitro and in vivo studies have demonstrated superior antifungal activity and skin retention of transferosome-loaded antifungal formulations compared to their conventional counterparts. Despite these promising attributes, challenges remain in the translation of transferosomal systems from research laboratories to commercial clinical products [8]. Issues such as vesicle stability, large-scale manufacturing, formulation cost, and regulatory approval need to be addressed. Moreover, variations in skin physiology across individuals, body sites, and disease states can affect drug penetration and therapeutic outcomes. This review explores the design, advantages, and mechanistic function of transferosomes in topical antifungal therapy. It highlights the most recent research on transferosome-mediated delivery of antifungal agents, discusses current formulation and application challenges, and provides insights into potential future directions such as stimuli-responsive transferosomes, hybrid nanocarriers, and personalized antifungal therapy [9]. By understanding the scientific rationale and therapeutic potential of transferosomes, we can develop more effective and patient-friendly approaches to treating superficial fungal infections and improving dermatological health outcomes.

2. Transferosome Structure and Mechanism

Transferosomes are advanced, ultra-deformable vesicular carriers specifically engineered to overcome the rigid barrier of the skin’s stratum corneum. Structurally, they resemble conventional liposomes but are uniquely enhanced with edge activators—a class of surfactants that impart extraordinary elasticity and flexibility to the lipid bilayer [10]. The fundamental components of a transferosome include phospholipids such as phosphatidylcholine, which form the basic bilayer structure, edge activators like Tween 80, Span 80, or sodium cholate, which reduce membrane rigidity, and an aqueous core that houses the therapeutic agent, whether hydrophilic or lipophilic.

The distinguishing feature of transferosomes lies in their mechanical deformability. This property enables them to pass through narrow pores in the skin—often five to ten times smaller than the vesicle’s diameter—without rupturing. This is achieved by their ability to respond dynamically to transdermal hydration gradients, particularly the water content difference between the outer and inner layers of the skin. The osmotic pressure gradient acts as a driving force, propelling the vesicles across the stratum corneum and into deeper epidermal and dermal tissues [11].

Once transferosomes penetrate the superficial skin barrier, they accumulate in the viable epidermis and dermis, where they gradually release their drug payload. This sustained and targeted delivery results in enhanced skin retention, increased drug bioavailability, and potentially prolonged therapeutic action. Importantly, because transferosomes do not disrupt the skin barrier like chemical enhancers or microneedles, they offer a non-invasive and biocompatible approach to transdermal drug delivery [12]. By exploiting the skin’s natural moisture gradient and utilizing flexible membrane engineering, transferosomes represent a cutting-edge solution for delivering antifungal agents to otherwise difficult-to-reach sites within the skin. Their ability to carry a wide range of drugs, combined with controlled release and minimal systemic exposure, makes them especially suitable for treating superficial fungal infections with improved efficacy and reduced side effects.

3. Advantages of Transferosomes in Antifungal Therapy

Transferosomes offer a range of benefits that address the limitations of conventional topical antifungal therapies. One of the most notable advantages is their enhanced skin penetration. Due to their ultra-deformable and elastic structure, transferosomes can traverse the stratum corneum—the primary barrier to drug absorption in the skin—and deliver antifungal agents to deeper layers such as the viable epidermis and dermis [13]. This ability ensures that drugs reach the site of fungal colonization more effectively, which is crucial for achieving rapid and sustained therapeutic outcomes [15]. Another important benefit is targeted drug delivery. By localizing drug action at the site of infection, transferosomes reduce the risk of systemic absorption and associated side effects. This localized approach not only enhances efficacy but also allows for lower drug doses, which further minimizes the potential for toxicity or irritation, especially important in sensitive or chronically affected skin.

Transferosomes also contribute to improved drug stability. Many antifungal agents are prone to degradation due to environmental factors such as light, temperature, or enzymatic activity. Encapsulating these agents within the vesicular structure can protect them from such degradation, thereby maintaining their bioactivity over an extended period [16]. The controlled and sustained release profile of transferosomes is another distinct advantage. These vesicles gradually release their payload once they reach the target tissue, allowing for prolonged therapeutic action. This reduces the need for frequent reapplication and enhances treatment adherence [17]. Finally, transferosomes support better patient compliance due to their non-invasive application, improved tolerability, and reduced dosing frequency. Together, these attributes make transferosomes a highly promising delivery platform for topical antifungal therapies, potentially revolutionizing the management of superficial fungal infections.

---

4. Recent Advances in Transferosomal Antifungal Formulations

Recent years have witnessed significant progress in the formulation of transferosome-based topical therapies for fungal infections [18]. Various antifungal agents have been successfully encapsulated within transferosomes, demonstrating improved pharmacokinetics and therapeutic outcomes compared to conventional formulations.

Clotrimazole, a broad-spectrum imidazole antifungal agent, has been incorporated into transferosomal carriers with remarkable success. Studies have reported that clotrimazole-loaded transferosomes exhibit significantly higher drug deposition in the stratum corneum and viable epidermis [19]. This improved permeation correlates with enhanced antifungal efficacy against common dermatophytes and yeasts, outperforming standard cream-based formulations.

Terbinafine, a widely used allylamine antifungal agent, has also benefited from transferosomal delivery. Transferosome-based terbinafine formulations have shown increased drug retention within epidermal layers and demonstrated superior fungal clearance in experimental dermatophytosis models [20]. Notably, these systems have reduced fungal load more effectively and with fewer applications, indicating improved bioavailability and sustained action.

Econazole and ketoconazole, both belonging to the azole class of antifungals, have also been explored in transferosomal systems [21]. These formulations have shown enhanced skin permeation and prolonged retention time in in vitro and in vivo models. Importantly, transferosome-encapsulation of these drugs has also been associated with reduced cytotoxicity and irritation potential, making them suitable for chronic or sensitive skin applications.

Transferosomal antifungal formulations have been evaluated across various fungal infections, including dermatophytosis, cutaneous candidiasis, and onychomycosis. In all cases, the vesicular systems demonstrated improved therapeutic efficacy, faster symptom resolution, and reduced recurrence rates compared to conventional treatments [22]. These findings underscore the clinical promise of transferosomes as next-generation vehicles for topical antifungal therapy.

5. Challenges and Limitations

Despite the numerous therapeutic advantages offered by transferosome-based antifungal formulations, several critical challenges hinder their broader clinical and commercial implementation. One of the primary concerns is formulation stability [23]. Transferosomes are prone to vesicle aggregation, drug leakage, or phospholipid oxidation over time, which can significantly reduce their shelf-life and therapeutic efficacy. Developing stable formulations that retain integrity under varying storage conditions remains a priority for researchers, the cost of production presents a major barrier. The use of high-purity phospholipids, specialized surfactants (edge activators), and advanced manufacturing equipment contributes to elevated production expenses, making these systems less accessible for routine use, particularly in low-resource settings [25]. Closely related to this is the challenge of scale-up. While many transferosomal formulations perform well at the laboratory scale, maintaining vesicle size uniformity, drug encapsulation efficiency, and reproducibility during industrial-scale manufacturing is complex and often problematic.

Regulatory challenges further limit the commercialization of transferosome-based drug products. There is currently a lack of harmonized and specific regulatory frameworks governing nanocarrier-based delivery systems, which leads to delays in approval and market entry. Moreover, the inclusion of edge activators such as sodium cholate or Tween 80, while essential for vesicle deformability, can sometimes cause local skin irritation or allergic responses, particularly in sensitive individuals. Thus, thorough dermatological testing and optimization of formulation components are critical for ensuring safety [26].

6. Future Perspectives

The field of transferosome-based topical antifungal therapy is rapidly evolving, offering exciting opportunities for innovation and clinical translation. One promising avenue is the development of hybrid nanocarrier systems, which involve integrating transferosomes with other delivery platforms such as liposomes, ethosomes, or polymeric nanoparticles. These hybrid systems can synergistically enhance drug encapsulation efficiency, stability, and skin permeability, while mitigating the limitations of each individual carrier. For instance, the incorporation of biocompatible polymers may improve vesicle rigidity and prolong shelf life without compromising deformability.

Another emerging area is the design of stimuli-responsive or “smart” transferosomes. These systems are engineered to release their payload in response to specific environmental cues, such as changes in pH, temperature, or the presence of fungal enzymes. Such precision delivery could significantly reduce off-target effects, improve therapeutic outcomes, and decrease dosing frequency, enhancing patient adherence. Despite encouraging preclinical results, clinical translation remains a key priority. There is a pressing need for well-designed, randomized clinical trials to assess the safety, efficacy, and long-term outcomes of transferosomal antifungal therapies in diverse patient populations. These trials will provide critical data for regulatory approval and facilitate the incorporation of such technologies into mainstream dermatological practice, the rise of personalized medicine offers another frontier for transferosome-based systems. By integrating patient-specific genomic data and microbiome profiling, it may be possible to tailor antifungal formulations to an individual’s unique susceptibility patterns, skin physiology, and microbial ecosystem. This personalized approach could greatly enhance therapeutic precision and minimize resistance development., these future directions underscore the potential of transferosomes not only as a drug delivery tool but also as a platform for next-generation dermatological therapies that are safe, effective, and tailored to individual needs.

---

7. Conclusion

Transferosomes have emerged as a promising nanocarrier system capable of overcoming the key limitations of conventional topical antifungal therapies. Their unique structure—comprising phospholipids and edge activators—endows them with exceptional deformability, allowing enhanced penetration through the stratum corneum and deeper skin layers. This facilitates improved drug bioavailability, targeted delivery, and sustained therapeutic action, ultimately leading to superior treatment outcomes.

Despite these advantages, certain challenges remain, including formulation instability, high production costs, and regulatory uncertainties. However, ongoing advancements in formulation science, materials engineering, and smart delivery technologies offer pathways to overcome these obstacles. As research transitions from preclinical evaluations to clinical trials, transferosome-based antifungal systems are poised to revolutionize the management of superficial fungal infections.

Given the increasing prevalence of antifungal resistance and frequent treatment failures with existing therapies, transferosomes offer a timely and innovative solution. With continued interdisciplinary research and clin

---

Author Statement

The author declares no conflict of interest.

References.

1. Ahuja, A., & Bajpai, M. (2024). Nanoformulations insights: a Novel paradigm for antifungal therapies and future perspectives. Current Drug Delivery, 21(9), 1241-1272.
2. Mishra, V., Singh, M., Mishra, Y., Charbe, N., Nayak, P., Sudhakar, K., … & Tambuwala, M. M. (2021). Nanoarchitectures in management of fungal diseases: An overview. Applied Sciences, 11(15), 7119.
3. Glujoy, M., Salerno, C., Bregni, C., & Carlucci, A. M. (2014). Percutaneous drug delivery systems for improving antifungal therapy effectiveness: A review. Int. J. Pharm. Pharm. Sci, 6, 8-16.
4. VijayKumar, R. (2020). Impact of Microbial Inoculants on Rice Growth and Yield in a Drumstick-Based Agroforestry System. Microbiology Archives, an International Journal.
5. Nirbhavane, P., Sharma, G., Verma, S., Jadon, R. S., Singh, B., & Katare, O. P. (2020). Nail psoriasis treatment: insights into current progress and future trends. Critical Reviews™ in Therapeutic Drug Carrier Systems, 37(2).
6. Thakur, K., Sharma, G., Singh, B., Chhibber, S., & Katare, O. P. (2018). Current state of nanomedicines in the treatment of topical infectious disorders. Recent Patents on Anti-Infective Drug Discovery, 13(2), 127-150.
7. Rajan, R., & Vasudevan, D. T. (2012). Effect of permeation enhancers on the penetration mechanism of transfersomal gel of ketoconazole. Journal of advanced pharmaceutical Technology & Research, 3(2), 112-116.
8. Pandey, R., Bhairam, M., Shukla, S. S., & Gidwani, B. (2021). Colloidal and vesicular delivery system for herbal bioactive constituents. DARU Journal of Pharmaceutical Sciences, 29(2), 415-438.
9. Upasani, R., Herwadkar, A., Singh, N., & Banga, A. K. (2020). Innovations and future prospects of dermal delivery systems. In Dermal Drug Delivery (pp. 415-438). CRC Press.
10. Kotla, N. G., Chandrasekar, B., Rooney, P., Sivaraman, G., Larrañaga, A., Krishna, K. V., & Rochev, Y. (2017). Biomimetic lipid-based nanosystems for enhanced dermal delivery of drugs and bioactive agents. ACS Biomaterials Science & Engineering, 3(7), 1262-1272.
11. Nagpal, M., & Kaur, M. (2021). Nanomaterials for skin antifungal therapy: An updated review. Journal of Applied Pharmaceutical Science, 11(1), 015-025.
12. Oyarzún, P., Gallardo-Toledo, E., Morales, J., & Arriagada, F. (2021). Transfersomes as alternative topical nanodosage forms for the treatment of skin disorders. Nanomedicine, 16(27), 2465-2489.
13. Aziz, Z. A. A., & Setapar, S. H. M. (2022). Current status and future prospect of nanotechnology incorporated plant-based extracts in cosmeceuticals. In Nanotechnology for the preparation of cosmetics using plant-based extracts (pp. 235-261). Elsevier.
14. Akram, M. W., Jamshaid, H., Rehman, F. U., Zaeem, M., Khan, J. Z., & Zeb, A. (2021). Transfersomes: a revolutionary nanosystem for efficient transdermal drug delivery. AAPS PharmSciTech, 23(1), 7.
15. VijayKumar, R. (2019). Microbial Interactions in Silviculture for Resilient Forest Ecosystems. Microbiology Archives, an International Journal.
16. Garg, V., Singh, H., Bimbrawh, S., Kumar Singh, S., Gulati, M., Vaidya, Y., & Kaur, P. (2017). Ethosomes and transfersomes: Principles, perspectives and practices. Current drug delivery, 14(5), 613-633.
17. Tewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Abdela Siraj, E. (2021). Targeted drug delivery—from magic bullet to nanomedicine: principles, challenges, and future perspectives. Journal of Multidisciplinary Healthcare, 1711-1724.
18. Sguizzato, M., Esposito, E., & Cortesi, R. (2021). Lipid-based nanosystems as a tool to overcome skin barrier. International journal of molecular sciences, 22(15), 8319.
19. Pahwa, R., Pal, S., Saroha, K., Waliyan, P., & Kumar, M. (2021). Transferosomes: Unique vesicular carriers for effective transdermal delivery. Journal of Applied Pharmaceutical Science, 11(5), 001-008.
20. Das Kurmi, B., Tekchandani, P., Paliwal, R., & Rai Paliwal, S. (2017). Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers. Current drug metabolism, 18(5), 481-495.
21. Gupta, N., Gupta, G. D., & Singh, D. (2022). Localized topical drug delivery systems for skin cancer: Current approaches and future prospects. Frontiers in Nanotechnology, 4, 1006628.
22. Akhtar, N., Verma, A., & Pathak, K. (2015). Topical delivery of drugs for the effective treatment of fungal infections of skin. Current pharmaceutical design, 21(20), 2892-2913.
23. Witika, B. A., Mweetwa, L. L., Tshiamo, K. O., Edler, K., Matafwali, S. K., Ntemi, P. V., … & Makoni, P. A. (2021). Vesicular drug delivery for the treatment of topical disorders: Current and future perspectives. Journal of Pharmacy and Pharmacology, 73(11), 1427-1441.
24. El-Zaafarany, G. M., & Nasr, M. (2021). Insightful exploring of advanced nanocarriers for the topical/transdermal treatment of skin diseases. Pharmaceutical development and technology, 26(10), 1136-1157.
25. Abdul Rasool, B. K., Al Mahri, N., Alburaimi, N., Abdallah, F., & Shamma, A. S. B. (2022). A narrative review of the potential roles of lipid-based vesicles (vesiculosomes) in burn management. Scientia Pharmaceutica, 90(3), 39.
26. Tapfumaneyi, P., Imran, M., Mohammed, Y., & Roberts, M. S. (2022). Recent advances and future prospective of topical and transdermal delivery systems. Frontiers in Drug Delivery, 2, 957732.